Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Resca – page 6

224 clinical trials in Resca, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Resca at a glance
224
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

224 trials in Resca

Open in trial search

Study of L-Annamycin and Cytarabine for Adults with Refractory or Relapsed Acute Myeloid Leukemia

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Annamycin
  • Sponsor:Moleculin Biotech Inc.

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Daiichi Sankyo Inc.

Gastric cancer+3

Recruiting

Study of HLX22, Trastuzumab, and Chemotherapy for Patients with Advanced or Metastatic Stomach and Gastroesophageal Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Shanghai Henlius Biotech Inc.

Study of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Amivantamab and Drug Combination for Patients with Recurrent or Metastatic Colorectal Cancer Without KRAS/NRAS and BRAF Mutations

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Study on Toripalimab and Tifcemalimab for Patients with Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

Investigational
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Tifcemalimab
  • Sponsor:Shanghai Junshi Biosciences Co. Ltd.

Study Comparing BMS-986489 with Chemotherapy to Atezolizumab with Chemotherapy for First-Line Treatment in Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Pembrolizumab and MK-2870 for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:OSE Immunotherapeutics

Study of BI-1206 and Pembrolizumab for Patients with Advanced Solid Tumors Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:BI-1206
  • Sponsor:BioInvent International AB

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Resca

What the registry says about research in the country

01 Infectious Disease Research

Ongoing clinical trials focusing on influenza prevention in elderly populations, evaluating advanced vaccine formulations with specialized adjuvants for enhanced immune response.

  • Vaccine Efficacy Studies
  • Immune Response Assessment
  • Prevention Strategies

Research aims to improve protection against influenza A and B strains through comparative analysis of adjuvanted and non-adjuvanted vaccine formulations in adults aged 65 and older.

02 Geriatric Medicine

Specialized vaccine research targeting the elderly population, with emphasis on developing more effective immunization strategies for vulnerable age groups.

  • Age-Specific Responses
  • Safety Monitoring
  • Immunogenicity Assessment

The research evaluates vaccine safety profiles and immune responses specifically tailored for older adults' unique health needs.

03 Vaccine Development

Advanced research into vaccine formulation technology, comparing different approaches to enhance protective immune responses against seasonal influenza.

  • Adjuvant Technology
  • Comparative Effectiveness
  • Clinical Protection

Studies focus on innovative vaccine technologies to improve prevention strategies against viral respiratory infections.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.